Potensi Terapi Antibodi Bispesifik sebagai Pengobatan Antikanker: Tinjauan Literatur
DOI:
https://doi.org/10.22225/amj.6.2.2026.462-469Keywords:
bispecific antibodies, cancer, immunotherapy, targeted therapyAbstract
Abstract
Bispecific antibodies are engineered antibodies capable of recognizing two targets simultaneously, thereby redirecting immune effector cells toward tumor cells or inhibiting two molecular pathways involved in cancer growth and therapeutic resistance. This literature review aimed to evaluate the mechanisms of action, efficacy, safety, and developmental challenges of bispecific antibodies in cancer treatment based on publications from 2020 to 2025. A literature search was conducted through Google Scholar using the phrase bispecific antibodies cancer therapy. Twenty articles were reviewed, comprising 17 primary studies and three review articles used as supporting sources. The investigated agents mainly acted through T-cell or natural killer-cell redirection, simultaneous blockade of two signaling pathways, and modulation of the tumor microenvironment. The strongest clinical evidence was identified for cadonilimab in cervical cancer, while zenocutuzumab demonstrated clinical activity in tumors harboring NRG1 fusions. Most other agents remained at the preclinical stage. Major challenges included cytokine release syndrome, immune-related toxicity, antigen heterogeneity, tumor resistance, and limited translation of preclinical efficacy into clinical benefit. Bispecific antibodies represent a promising therapeutic approach in oncology; however, their clinical implementation requires biomarker-guided patient selection, dose optimization, and comprehensive safety evaluation in adequately designed clinical trials.
Keywords: bispecific antibodies, cancer, immunotherapy, targeted therapy.
References
DAFTAR PUSTAKA
1. Gera N. The evolution of bispecific antibodies. Expert Opin Biol Ther. 2022;22(8):945-949. doi:10.1080/14712598.2022.2040987.
2. Zhang J, Yi J, Zhou P. Development of bispecific antibodies in China: overview and prospects. Antib Ther. 2020;3(2):126-145. doi:10.1093/abt/tbaa011.
3. Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, et al. Synergistic efficacy of simultaneous anti-TGF-?/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023;16:94. doi:10.1186/s13045-023-01487-5.
4. El Zawily A, Vizeacoumar FS, Dahiya R, Banerjee SL, Bhanumathy KK, Elhasasna H, et al. A multipronged unbiased strategy guides the development of an anti-EGFR/EPHA2-bispecific antibody for combination cancer therapy. Clin Cancer Res. 2023;29(14):2686-2701. doi:10.1158/1078-0432.CCR-22-2535.
5. Liu H, Bai L, Huang L, Ning N, Li L, Li Y, et al. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer. J Immunother Cancer. 2021;9(10):e003468. doi:10.1136/jitc-2021-003468.
6. Cho BC, Lee JS, Wu YL, et al. Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial. J Thorac Oncol. 2023;18(12):1731-1742. doi:10.1016/j.jtho.2023.08.018.
7. Simoni-Nieves A, Lindzen M, Giri S, Gupta N, Chatterjee R, Selvadurai BR, et al. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib. Cell Rep Med. 2024;5(9):101703. doi:10.1016/j.xcrm.2024.101703.
8. Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. Cancer Discov. 2022;12(5):1233-1247. doi:10.1158/2159-8290.CD-21-1119.
9. Lin TY, Park JA, Long A, Guo HF, Cheung NV. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy. J Immunother Cancer. 2021;9(9):e003114. doi:10.1136/jitc-2021-003114.
10. Zhao Y, Li Y, Wu X, Li L, Liu J, Wang Y, et al. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies. Cancer Biol Ther. 2020;21(1):72-80. doi:10.1080/15384047.2019.1665953.
11. Wu X, Sun Y, Yang H, Wang J, Lou H, Li D, et al. Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. Lancet. 2024;404(10463):1668-1676. doi:10.1016/S0140-6736(24)02135-4.
12. Qiao G, Kone LB, Phillips EH, Lee SSY, Brown GE, Khetani SR, et al. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer. Oncogene. 2022;41(14):2054-2068. doi:10.1038/s41388-022-02209-w.
13. Boustany LM, LaPorte SL, Wong L, White C, Vinod V, Shen J, et al. A Probody T cell-engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity. Cancer Res. 2022;82(22):4288-4298. doi:10.1158/0008-5472.CAN-21-2483.
14. Sun R, Zhou Y, Han L, Pan Z, Chen J, Zong H, et al. A rationally designed novel bispecific antibody for the treatment of glioblastoma. Biomedicines. 2021;9(6):640. doi:10.3390/biomedicines9060640.
15. Zekri L, Lutz M, Prakash N, Manz T, Klimovich B, Mueller S, et al. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. Mol Ther. 2023;31(4):1033-1045. doi:10.1016/j.ymthe.2023.02.010.
16. Chen J, Pan Z, Han L, Zhou Y, Zong H, Wang L, et al. A novel bispecific antibody targeting CD3 and Lewis Y with potent therapeutic efficacy against gastric cancer. Biomedicines. 2021;9(8):1059. doi:10.3390/biomedicines9081059.
17. Lutz S, Klausz K, Albici AM, Ebinger L, Sellmer L, Teipel H, et al. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells. Front Immunol. 2023;14:1227572. doi:10.3389/fimmu.2023.1227572.
18. Lee SC, Ma JSY, Kim MS, Laborda E, Choi SH, Hampton EN, et al. A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Sci Adv. 2021;7(33):eabi8193. doi:10.1126/sciadv.abi8193.
19. Yang H, Karl MN, Wang W, Starich B, Tan H, Kiemen A, et al. Engineered bispecific antibodies targeting the interleukin-6 and interleukin-8 receptors potently inhibit cancer cell migration and tumor metastasis. Mol Ther. 2022;30(11):3430-3449. doi:10.1016/j.ymthe.2022.07.008.
20. Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9(1):175. doi:10.1038/s41392-024-01856-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Yurafi Kun Naviaghani, Muhammad Aziz Hidayat
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
